VSTM
$2.01
Verastem
$.04
2.03%
VSTM
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.33)
Revenue:  $5.11 Mil
Tuesday
Mar 10
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VSTM reports earnings?
Beat
Meet
Miss

Where is VSTM's stock price going from here?
Up
Flat
Down
Stock chart of VSTM
Analysts
Summary of analysts' recommendations for VSTM
Score
Grade
Pivots
Resistance
$2.24
$2.16
$2.07

$1.99

Support
$1.90
$1.82
$1.73
Tweet
Growth
Description
Verastem, Inc. is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. The company discovers, researches, and develops new medicines for the treatment of major cancers such as breast cancer. Verastem, Inc. is based in Cambridge, Massachusetts.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptZoetisJohnson & JohnsonMylanUltragenyx PharmaceuticalBristol-Myers SquibbAlkermes